-
Posted by
Two Blokes Apr 16 -
Filed in
Stock
-
2 views
We initiate a Buy rating for Benitec Biopharma due to promising early data from BB 301 for OPMD and a cash runway into mid-2027. BB 301 shows potential for meaningful improvements in swallowing function, with significant commercial opportunities and an undervalued stock price reflecting high-dose cohort data. Financially, Benitec has no revenue, rising operating expenses, and a cash balance of $78.3 million, providing a runway into mid-2027, though burn rate may increase.
